JP2024023228A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023228A5 JP2024023228A5 JP2023188623A JP2023188623A JP2024023228A5 JP 2024023228 A5 JP2024023228 A5 JP 2024023228A5 JP 2023188623 A JP2023188623 A JP 2023188623A JP 2023188623 A JP2023188623 A JP 2023188623A JP 2024023228 A5 JP2024023228 A5 JP 2024023228A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- molecule
- hla
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506674P | 2017-05-16 | 2017-05-16 | |
| US62/506,674 | 2017-05-16 | ||
| PCT/US2018/032996 WO2018213467A1 (en) | 2017-05-16 | 2018-05-16 | Manabodies and methods of using |
| JP2019563546A JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Division JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024023228A JP2024023228A (ja) | 2024-02-21 |
| JP2024023228A5 true JP2024023228A5 (enExample) | 2024-08-01 |
| JP7701079B2 JP7701079B2 (ja) | 2025-07-01 |
Family
ID=64274676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Active JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
| JP2023188623A Active JP7701079B2 (ja) | 2017-05-16 | 2023-11-02 | Ｍａｎａボディおよび使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Active JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11807662B2 (enExample) |
| EP (2) | EP4644427A3 (enExample) |
| JP (2) | JP7381345B2 (enExample) |
| CN (1) | CN111406068A (enExample) |
| AU (2) | AU2018269370B2 (enExample) |
| CA (1) | CA3063905A1 (enExample) |
| WO (1) | WO2018213467A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11807662B2 (en) | 2017-05-16 | 2023-11-07 | The Johns Hopkins University | MANAbodies and methods of using |
| EP3683229A1 (en) * | 2019-01-21 | 2020-07-22 | Charité - Universitätsmedizin Berlin | Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy |
| GB2613715B (en) * | 2019-02-20 | 2023-12-06 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| IL266728B (en) * | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
| WO2021098822A1 (zh) * | 2019-11-21 | 2021-05-27 | 江苏恒瑞医药股份有限公司 | 一种双特异性抗体 |
| WO2021127184A1 (en) * | 2019-12-17 | 2021-06-24 | The Johns Hopkins University | MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| WO2021255189A1 (en) * | 2020-06-17 | 2021-12-23 | Tiziana Life Sciences, Plc | Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies |
| CN116867519A (zh) * | 2020-12-01 | 2023-10-10 | 约翰斯霍普金斯大学 | 治疗t细胞癌症的方法和材料 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CN116574748B (zh) * | 2023-07-10 | 2023-09-12 | 昆明医科大学 | 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法 |
| CN122438861A (zh) * | 2023-11-13 | 2026-07-21 | 克拉斯普治疗有限公司 | 靶向肿瘤抗原并接合t细胞受体的修饰的mana-tce及其使用方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| US6630584B1 (en) | 2000-03-16 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Single chain antibody against mutant p53 |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| JP3738308B2 (ja) | 2002-11-29 | 2006-01-25 | 篤 村口 | 抗原特異的リンパ球抗原受容体遺伝子のクローニング方法 |
| MXPA05014155A (es) | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
| WO2005099361A2 (en) | 2003-07-10 | 2005-10-27 | Vaccinex, Inc. | MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN |
| EP1712620A4 (en) * | 2004-01-23 | 2008-05-28 | Greenpeptide Co Ltd | EGF (EPIDERMAL GROWTH FACTOR) RECEPTOR-ORGANIC PEPTIDE |
| US20060034850A1 (en) | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| WO2006100681A2 (en) | 2005-03-25 | 2006-09-28 | Ramot At Tel Aviv University Ltd. | Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses |
| CN101228187A (zh) | 2005-03-25 | 2008-07-23 | 特拉维夫大学拉莫特有限公司 | 针对突变p53的共同表位的人合成单链抗体及其用途 |
| AU2006291005A1 (en) | 2005-09-12 | 2007-03-22 | Novimmune S.A. | Anti-CD3 antibody formulations |
| JP2009521474A (ja) | 2005-12-21 | 2009-06-04 | メディミューン，エルエルシー | ＥｐｈＡ２ＢｉＴＥ分子およびその使用 |
| EA201401134A1 (ru) | 2011-02-11 | 2015-05-29 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Hla-рестиктированные пептидоспецифические антигенсвязывающие белки |
| WO2012162067A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| ES2765710T3 (es) | 2014-04-03 | 2020-06-10 | Cellectis | Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer |
| US9611325B2 (en) | 2014-07-21 | 2017-04-04 | Wuhan Yzy Biopharma Co., Ltd. | Construction and application of bispecific antibody HER2xCD3 |
| SG10201913978RA (en) * | 2014-11-26 | 2020-03-30 | The United States Of America As Represented By The Secretary | Anti-mutated kras t cell receptors |
| WO2016154047A2 (en) * | 2015-03-20 | 2016-09-29 | Memorial Sloan-Kettering Cancer Center | Monoclonal antigen-binding proteins to intracellular oncogene products |
| EP3286222A4 (en) * | 2015-03-23 | 2018-08-08 | The Johns Hopkins University | Hla-restricted epitopes encoded by somatically mutated genes |
| WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| JP6913032B2 (ja) * | 2015-05-20 | 2021-08-04 | ザ・ブロード・インスティテュート・インコーポレイテッド | 共通ネオ抗原 |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| IL281396B (en) | 2015-06-09 | 2022-07-01 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| SG10201913868XA (en) | 2015-09-15 | 2020-03-30 | The United States Of America As Represented By The Secretary | T cell receptors recognizing hla-cw8 restricted mutated kras |
| UA126657C2 (uk) | 2016-02-03 | 2023-01-11 | Емджен Рісерч (Мюнік) Ґмбг | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> |
| AR107582A1 (es) | 2016-02-03 | 2018-05-16 | Amgen Res Munich Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| CA3034093A1 (en) * | 2016-08-23 | 2018-03-01 | The Regents Of The University Of California | Proteolytically cleavable chimeric polypeptides and methods of use thereof |
| US20190240257A1 (en) | 2016-10-13 | 2019-08-08 | The Johns Hopkins University | Compositions and methods for identifying functional anti-tumor t cell responses |
| US20200325244A1 (en) * | 2020-05-18 | 2020-10-15 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| US11807662B2 (en) | 2017-05-16 | 2023-11-07 | The Johns Hopkins University | MANAbodies and methods of using |
| JP7391015B2 (ja) | 2017-09-29 | 2023-12-04 | アメリカ合衆国 | Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法 |
| MX2020005765A (es) * | 2017-12-04 | 2020-09-25 | Us Health | Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. |
| WO2021127184A1 (en) | 2019-12-17 | 2021-06-24 | The Johns Hopkins University | MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING |
| WO2021127814A1 (zh) | 2019-12-23 | 2021-07-01 | 深圳市人民医院 | 用于癌症治疗的光纳米疫苗及其制备方法和应用 |
-
2018
- 2018-05-16 US US16/614,005 patent/US11807662B2/en active Active
- 2018-05-16 WO PCT/US2018/032996 patent/WO2018213467A1/en not_active Ceased
- 2018-05-16 CA CA3063905A patent/CA3063905A1/en active Pending
- 2018-05-16 CN CN201880047554.3A patent/CN111406068A/zh active Pending
- 2018-05-16 AU AU2018269370A patent/AU2018269370B2/en active Active
- 2018-05-16 JP JP2019563546A patent/JP7381345B2/ja active Active
- 2018-05-16 EP EP25190769.7A patent/EP4644427A3/en active Pending
- 2018-05-16 EP EP18802867.4A patent/EP3635000A4/en not_active Withdrawn
-
2023
- 2023-09-25 US US18/473,695 patent/US20240294648A1/en active Pending
- 2023-11-02 JP JP2023188623A patent/JP7701079B2/ja active Active
-
2025
- 2025-05-21 AU AU2025203767A patent/AU2025203767A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023507729A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2022109953A5 (enExample) | ||
| JP2023518134A5 (enExample) | ||
| WO2021008610A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| JP2021512635A5 (enExample) | ||
| JP2023123502A5 (enExample) | ||
| JP2025142045A5 (enExample) | ||
| JP2019525771A5 (enExample) | ||
| RU2019126655A (ru) | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль | |
| JP2021536265A5 (enExample) | ||
| JP2018538277A5 (enExample) | ||
| JP2018526033A5 (enExample) | ||
| JP2022542559A5 (enExample) | ||
| JP2020512973A5 (enExample) | ||
| JP2019535262A5 (enExample) | ||
| CN115066274A (zh) | 三价结合分子 | |
| CN105194661A (zh) | 时空可调性抑制病理性靶细胞的系统 | |
| JP2023502108A5 (enExample) | ||
| JP2022513372A5 (enExample) | ||
| IL274806B1 (en) | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof | |
| JP2024510739A5 (enExample) | ||
| JP2024511423A5 (enExample) | ||
| JP2024504162A5 (enExample) |